Company intelligence / Profile preview
Daewoong Therapeutics
Suwon-si, Gyeonggi-do, South Korea
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Daewoong Therapeutics has received approval for Phase 1 clinical trials for a human growth hormone microneedle patch, the first dissolvable microneedle in Korea. Their DWP213388 targeting BTK and ITK has received approval for U.S. Phase 1 Clinical Trials. Bersiporocin (DWN12088) for IPF is in Phase 2 trials in the US and Korea.
- Therapeutic areas
- OncologyPulmonologyEndocrinologyImmunologyOphthalmology
- Modalities
- Small moleculesPeptidesMicroneedle drug delivery systems
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
AEON BiopharmaEvolus
Beyond the preview
Go deeper on Daewoong Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Daewoong Therapeutics.